HAE
Income statement / Annual
Last year (2025), Haemonetics Corporation's total revenue was $1.36 B,
an increase of 3.95% from the previous year.
In 2025, Haemonetics Corporation's net income was $167.68 M.
See Haemonetics Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
03/29/2025 |
03/30/2024 |
04/01/2023 |
04/02/2022 |
04/03/2021 |
03/28/2020 |
03/30/2019 |
03/31/2018 |
04/01/2017 |
04/02/2016 |
| Operating Revenue |
$1.36 B |
$1.31 B |
$1.17 B |
$993.20 M |
$870.46 M |
$988.48 M |
$967.58 M |
$903.92 M |
$886.12 M |
$909.68 M |
| Cost of Revenue |
$611.87 M
|
$617.51 M
|
$553.56 M
|
$487.69 M
|
$472.63 M
|
$503.97 M
|
$550.04 M
|
$492.02 M
|
$507.62 M
|
$503.80 M
|
| Gross Profit |
$748.96 M
|
$691.55 M
|
$615.10 M
|
$505.50 M
|
$397.84 M
|
$484.51 M
|
$417.54 M
|
$411.91 M
|
$378.49 M
|
$405.87 M
|
| Gross Profit Ratio |
0.55
|
0.53
|
0.53
|
0.51
|
0.46
|
0.49
|
0.43
|
0.46
|
0.43
|
0.45
|
| Research and Development Expenses |
$62.72 M
|
$54.44 M
|
$50.13 M
|
$46.80 M
|
$32.86 M
|
$30.88 M
|
$35.71 M
|
$39.23 M
|
$37.56 M
|
$45.57 M
|
| General & Administrative Expenses |
$0.00
|
$424.68 M
|
$369.48 M
|
$335.16 M
|
$271.49 M
|
$295.38 M
|
$293.78 M
|
$313.42 M
|
$299.23 M
|
$320.07 M
|
| Selling & Marketing Expenses |
$0.00
|
$7.10 M
|
$7.20 M
|
$4.40 M
|
$2.70 M
|
$4.30 M
|
$4.50 M
|
$3.10 M
|
$2.50 M
|
$3.90 M
|
| Selling, General & Administrative Expenses |
$436.79 M
|
$431.78 M
|
$376.68 M
|
$339.56 M
|
$274.19 M
|
$299.68 M
|
$298.28 M
|
$316.52 M
|
$301.73 M
|
$323.97 M
|
| Other Expenses |
$27.63 M
|
$40.45 M
|
$32.26 M
|
$47.41 M
|
$32.83 M
|
$50.60 M
|
$0.00
|
$0.00
|
-$8.10 M
|
$87.67 M
|
| Operating Expenses |
$527.14 M
|
$526.67 M
|
$459.06 M
|
$433.78 M
|
$339.88 M
|
$330.56 M
|
$333.99 M
|
$355.75 M
|
$339.28 M
|
$369.54 M
|
| Cost And Expenses |
$1.14 B
|
$1.14 B
|
$459.06 M
|
$921.47 M
|
$812.50 M
|
$834.53 M
|
$884.03 M
|
$847.77 M
|
$846.90 M
|
$873.34 M
|
| Interest Income |
$0.00
|
$0.00
|
$13.00 M
|
$5.80 M
|
$9.40 M
|
$13.50 M
|
$9.91 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$9.75 M
|
$13.02 M
|
$14.63 M
|
$17.12 M
|
$16.83 M
|
$16.20 M
|
$9.91 M
|
$4.53 M
|
$8.10 M
|
$9.47 M
|
| Depreciation & Amortization |
$0.00
|
$97.22 M
|
$93.31 M
|
$97.75 M
|
$84.29 M
|
$110.29 M
|
$109.42 M
|
$89.25 M
|
$89.73 M
|
$89.91 M
|
| EBITDA |
$221.82 M |
$265.58 M |
$249.34 M |
$178.50 M |
$142.25 M |
$264.24 M |
$192.96 M |
$153.03 M |
$70.35 M |
$45.97 M |
| EBITDA Ratio |
0.16
|
0.2
|
0.21
|
0.18
|
0.16
|
0.27
|
0.2
|
0.17
|
0.08
|
0.05
|
| Operating Income Ratio |
0.16
|
0.13
|
0.13
|
0.08
|
0.07
|
0.16
|
0.09
|
0.06
|
-0.02
|
-0.05
|
| Total Other Income/Expenses Net |
-$9.75 M
|
-$54.97 M
|
-$14.63 M
|
-$17.12 M
|
$14.95 M
|
-$16.20 M
|
-$9.91 M
|
$3.48 M
|
-$8.10 M
|
-$97.14 M
|
| Income Before Tax |
$212.07 M
|
$151.87 M
|
$141.40 M
|
$63.63 M
|
$72.91 M
|
$87.15 M
|
$73.63 M
|
$59.63 M
|
-$27.48 M
|
-$53.46 M
|
| Income Before Tax Ratio |
0.16
|
0.12
|
0.12
|
0.06
|
0.08
|
0.09
|
0.08
|
0.07
|
-0.03
|
-0.06
|
| Income Tax Expense |
$44.39 M
|
$34.31 M
|
$26.00 M
|
$20.25 M
|
-$6.56 M
|
$10.63 M
|
$18.61 M
|
$14.06 M
|
-$1.21 M
|
$2.16 M
|
| Net Income |
$167.68 M
|
$117.56 M
|
$115.40 M
|
$43.38 M
|
$79.47 M
|
$76.53 M
|
$55.02 M
|
$45.57 M
|
-$26.27 M
|
-$55.62 M
|
| Net Income Ratio |
0.12
|
0.09
|
0.1
|
0.04
|
0.09
|
0.08
|
0.06
|
0.05
|
-0.03
|
-0.06
|
| EPS |
3.31 |
2.32 |
2.27 |
0.85 |
1.57 |
1.51 |
1.07 |
0.86 |
-0.51 |
-1.09 |
| EPS Diluted |
3.31 |
2.29 |
2.24 |
0.84 |
1.55 |
1.48 |
1.04 |
0.85 |
-0.51 |
-1.09 |
| Weighted Average Shares Out |
$50.33 M
|
$50.71 M
|
$50.78 M
|
$51.05 M
|
$50.69 M
|
$50.69 M
|
$51.53 M
|
$52.76 M
|
$51.51 M
|
$50.91 M
|
| Weighted Average Shares Out Diluted |
$50.73 M
|
$51.40 M
|
$51.42 M
|
$51.35 M
|
$51.29 M
|
$51.82 M
|
$52.94 M
|
$53.50 M
|
$51.52 M
|
$50.91 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
